Press releasePRNewswire
Alzamend Neuro
ALZN · NASDAQ
$1.30−$0.03 (−2.26%)TodayMarket closed ·
Prev close $1.33
Latest news
- Press releasePRNewswire
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
- Press releasePRNewswire
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
- Press releasePRNewswire
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
- Press releasePRNewswire
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate
- Press releasePRNewswire
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
- Press releasePRNewswire
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
- News
10 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
- NewsAvi Kapoor
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
- NewsVandana Singh
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
- NewsVandana Singh
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits
- Press releaseBusiness Wire
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
- NewsVandana Singh
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels
- Press releaseBusiness Wire
Alzamend Neuro to Present at the Sequire Investor Summit
- Press releaseBusiness Wire
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
- Press releaseBusiness Wire
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
- Press releaseBusiness Wire
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice
- Press releaseBusiness Wire
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's
- Press releaseBusiness Wire
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- Press releaseBusiness Wire
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group's Virtual Healthcare Conference
- Press releaseBusiness Wire
Alzamend Neuro Issues Letter to Stockholders
- NewsAvi Kapoor
Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- News
Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today
- NewsAvi Kapoor
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
- NewsAvi Kapoor
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- NewsAvi Kapoor
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results
- NewsVandana Singh
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
- Press releaseBusiness Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
- Press releaseBusiness Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
- Press releaseBusiness Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.